Fasting Blood Glucose and 2-h Postprandial Blood Glucose Predict Hypertension: A Report from the REACTION Study.

2-h postprandial glucose Fasting blood glucose Glycated hemoglobin Hypertension Prediabetes

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 18 11 2020
accepted: 30 01 2021
pubmed: 5 3 2021
medline: 5 3 2021
entrez: 4 3 2021
Statut: ppublish

Résumé

Although diabetes is associated with hypertension, whether high blood glucose levels promote hypertension remains controversial. In this study we compared the predictive power of fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), and glycated hemoglobin (HbA1c) for the development of hypertension. This study was a substudy of the REACTION study, an ongoing longitudinal cohort study investigating the relationship of prediabetes and type 2 diabetes with the risk of cancer in an urban Northern Chinese population in Beijing. Logistic regression analysis was used to calculate odds ratios (ORs) after adjustment for risk factors for hypertension, including age, sex, body mass index, and triglycerides. Among the 3437 participants, 497 developed hypertension during the 4-year follow-up. The logistic regression analysis showed that elevated FPG and 2hPG levels (FPG: OR 1.529; 95% confidence interval [CI] 1.348-1.735; 2hPG: OR 1.144; 95% CI 1.100-1.191), but not HbA1c, were independent risk factors for the development of hypertension. In the highest quartile of FPG and 2hPG levels, the multivariable-corrected ORs were 2.115 (95% CI 1.612-2.777) and 2.346 (95% CI 1.787-3.080), respectively, compared with the lowest quartile. The adjusted models showed no significant correlations between quartile HbA1c levels and the development of hypertension. Higher FPG and 2hPG levels, but not HbA1c levels, are independent risk factors for developing hypertension in an urban Northern Chinese population. ClinicalTrials.gov NCT01206869.

Identifiants

pubmed: 33660197
doi: 10.1007/s13300-021-01019-9
pii: 10.1007/s13300-021-01019-9
pmc: PMC7994488
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1117-1128

Subventions

Organisme : Key Technologies Research and Development Program
ID : 2018YFC1314100

Références

Am J Hypertens. 2011 Mar;24(3):328-34
pubmed: 21151012
Curr Atheroscler Rep. 2012 Apr;14(2):160-6
pubmed: 22281657
Am J Hypertens. 2015 Apr;28(4):493-500
pubmed: 25267735
Lipids Health Dis. 2017 Sep 13;16(1):175
pubmed: 28903774
Circ Res. 2019 Mar 15;124(6):930-937
pubmed: 30646822
Am J Hypertens. 2019 Nov 15;32(12):1178-1185
pubmed: 31365923
Kidney Int. 2015 Mar;87(3):497-9
pubmed: 25723632
J Hypertens. 2020 Feb;38(2):369-371
pubmed: 31913952
J Hypertens. 2020 Jan;38(1):38-44
pubmed: 31386636
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
J Hypertens. 2019 Jan;37(1):167-174
pubmed: 30507865
Diabetes Care. 1999 Feb;22(2):228-32
pubmed: 10333938
Hypertension. 2006 Mar;47(3):403-9
pubmed: 16432042
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Diabetes Care. 2010 Sep;33(9):2104-9
pubmed: 20573754
Cardiovasc Diabetol. 2019 Apr 27;18(1):53
pubmed: 31029146
Nat Rev Endocrinol. 2019 Feb;15(2):75-89
pubmed: 30531917
Diabetologia. 1996 Jan;39(1):70-6
pubmed: 8720605
Diabetes Care. 2021 Jan;44(Suppl 1):S1-S2
pubmed: 33298409
Eur J Epidemiol. 2019 Sep;34(9):853-861
pubmed: 31399939
Diabetes Care. 2011 May;34 Suppl 2:S184-90
pubmed: 21525453
Diabetes Care. 2008 Sep;31(9):1889-91
pubmed: 18556342
J Diabetes Complications. 2017 Jul;31(7):1090-1095
pubmed: 28433447
J Hypertens. 2012 Jul;30(7):1440-3
pubmed: 22573126
BMC Endocr Disord. 2016 Jul 13;16(1):40
pubmed: 27412111
Lancet. 2012 Aug 11;380(9841):601-10
pubmed: 22883509
J Hum Hypertens. 2008 Mar;22(3):168-76
pubmed: 18046430
Lancet. 2007 Aug 18;370(9587):591-603
pubmed: 17707755
Diabetes Care. 2003 May;26(5):1333-7
pubmed: 12716784
Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):126-30
pubmed: 16187399
Am J Hypertens. 2018 Aug 3;31(9):1042-1048
pubmed: 29931224
J Hum Hypertens. 2015 Apr;29(4):254-9
pubmed: 25231510

Auteurs

Yingkui Si (Y)

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
Department of Endocrinology, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.

Anping Wang (A)

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.

Yunshuang Yang (Y)

Department of Preventive Medicine, Beijing Longfu Hospital, Beijng, China.

Hongzhou Liu (H)

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.

Shi Gu (S)

Department of Endocrinology, The First People's Hospital of Shuangliu District, Chengdu, China.

Yiming Mu (Y)

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China. muyiming@301hospital.com.cn.

Zhaohui Lyu (Z)

Department of Endocrinology, Chinese PLA General Hospital, Beijing, China. metabolism301@126.com.

Classifications MeSH